Serum KL-6 identifies ILD patients with a progressive fibrosing phenotype Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more Year: 2020
Serum KL-6 as a multidimensional biomarker in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016
Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis Source: Annual Congress 2004 - Fibrosing lung diseases Year: 2004
Diagnostic utility of serum KL-6 levels in acute respiratory failure with bilateral pulmonary infiltrates Source: Virtual Congress 2020 – Experimental and laboratory studies in intensive care unit medicine Year: 2020
The evaluation of serum biomarkers in patients with sarcoidosis: Can visfatin be a new biomarker for sarcoidosis? Source: International Congress 2017 – Rare diseases Year: 2017
Increased CCL18 serum levels in patients with pulmonary fibrosis which reflect disease severity Source: Eur Respir J 2005; 26: Suppl. 49, 21s Year: 2005
Serial change in serum KL-6 levels correlate with the pulmonary function variables in cystic fibrosis Source: Annual Congress 2010 - Cystic fibrosis: lung disease and much more Year: 2010
Prognostic role of CCL18 serum concentrations in patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2007; 30: Suppl. 51, 574s Year: 2007
KL-6 is a useful serum biomarker for early detection of interstitial lung disease Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012
Serum progranulin levels in idiopathic pulmonary fibrosis and other interstitial lung diseases Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF) Year: 2018
Relationship between MIF and cellular pattern in BAL of patients with sarcoidosis, systemic sclerosis, idiopathic pulmonary fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 377s Year: 2003
Annual changes of serum KL-6 were inversely correlated with those of respiratory function parameters in patients with nonspecific interstitial pneumonia Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease Year: 2010
Serum chitotriosidase levels in granulomatous lung disorders Source: Annual Congress 2006 - Clinical features and disease markers of sarcoidosis Year: 2006
Modified GAP index by including serum KL-6 to assess risk of disease progression in patients with interstitial lung diseases (ILD): preliminary results from the VAMOS study. Source: Virtual Congress 2021 – New approaches to diagnostic and prognostic evaluation of interstitial lung diseases of known causes Year: 2021
Correlation of HRCT proven inflammatory changes with serum levels of ACE, sIL-2r and calciuria in pulmonary sarcoidosis Source: Eur Respir J 2003; 22: Suppl. 45, 226s Year: 2003
Serum CYFRA reflects disease severity of autoimmune pulmonary alveolar proteinosis Source: Annual Congress 2010 - Rare diffuse lung diseases Year: 2010
Serum exosomes from IPF patients display a fibrotic miRNA profile that correlates to clinical measures of disease severity Source: International Congress 2015 – Interstitial lung diseases II Year: 2015
Pulmonary findings of the patients with Sjogren syndrome Source: Annual Congress 2012 - Cystic lung diseases: lung granulomatosis Year: 2012
Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis Source: Eur Respir J 2002; 19: 439-446 Year: 2002
Investigation of KL-6 levels in patients with IPF- OSA overlap syndrome: Preliminary results Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016